Mortimer Ian (PRESIDENT & CEO) bought $1.1M of stock
SEC Form 4
Xenon Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: every model's value for Xenon Pharmaceuticals Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.
Price vs value
Under review: limited reported history: available models are shown without a Buy/Hold/Sell rating. We'll show the comparison once resolved.
Xenon Pharmaceuticals Inc. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 6 selling2 purchases and 26 sales by directors and officers, last 12 monthsInsider trades
- Funds169 adding, 109 cuttingOf 66 active managers that changed their stake, 34 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Several insiders buying shares: 2 insiders bought shares in the open market in the past 90 days, according to their Form 4 filings.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Xenon Pharmaceuticals Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 68% and a beta of 0.8 against the S&P 500.
Latest results
- Earnings per share
- -$1.11 against an average estimate of -$1.16: beat by 4.4%
- Share reaction
- -1.5% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
- Next report
- November 2, 2026; average EPS estimate -$1.15
Price chart
- 1 day+2.0%
- 1 week+6.6%
- 1 month+0.9%
- This year-16.1%
- 1 year-6.7%
- 5 years+10.3%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 6, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Results
Xenon Pharmaceuticals Inc. reported results; made a public disclosure
SEC 8-KRead source ↗
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$4.63 | −6% | $1m | −83% |
| Next | −$4.72 | −2% | $27m | +2046% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −3.8% on 90 days ago. In the last 30 days, 1 analyst raised Xenon Pharmaceuticals Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$4.81 | −$5.03 |
| 60 days ago | −$4.63 | −$4.87 |
| 30 days ago | −$4.63 | −$4.71 |
| 7 days ago | −$4.63 | −$4.72 |
| Now | −$4.63 | −$4.72 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$1.16 | −$1.11 | +4.4% |
| Mar 2026 | −$1.20 | −$1.17 | +2.3% |
| Dec 2025 | −$1.21 | −$1.31 | −8.7% |
| Sept 2025 | −$1.16 | −$1.15 | +1.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 7.6% of tradable shares
- Days to cover
- 2.61 at average volume
- Short interest, 1 month
- +14% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 0.2% of shares
- Employees
- 358 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| XENE | +103% | +26% | +17% | −15% | +14% | −16% |
| Industry peers (median) | −36% | −57% | −18% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| XENE | 58% | 58% | 42% | 42% | 67% | 55% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| XENE | −30% | −28% | −34% | −28% | −31% | −53% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 78% from March 23, 2017 to November 14, 2017. Getting back needed a 348% gain, reached on July 6, 2018, 234 days after the low.
Price behaviour
- 52-week range
- $33.49 – $70.96
- From 52-week high
- −47.0%
- vs 50-day average
- −16.2%
- vs 200-day average
- −28.1%
- Volatility (1 year)
- 68%
- Beta vs S&P 500
- 0.77
Share price after results
- Next day
- 1 up, 11 down typical move ±5.3%
- After a week
- 1 up, 11 down typical move ±6.9%
- After a month
- 4 up, 8 down typical move ±11.4%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | −1.5% | +0.5% | −0.1% | −7.1% |
| May 7, 2026 | −3.7% | +0.5% | −4.4% | −12.6% |
| February 26, 2026 | −3.0% | −1.0% | −5.7% | +22.2% |
| November 3, 2025 | −6.8% | −1.0% | −8.4% | +5.7% |
| August 11, 2025 | +7.7% | +0.9% | +13.1% | +11.0% |
| May 12, 2025 | −15.5% | +4.0% | −11.6% | −7.9% |
| February 27, 2025 | −5.3% | −0.1% | −4.7% | −12.4% |
| November 12, 2024 | −4.8% | −0.3% | −11.8% | −10.5% |
| August 8, 2024 | −1.7% | +2.8% | −5.3% | −4.4% |
| May 9, 2024 | −5.6% | +0.7% | −6.0% | −10.9% |
| February 29, 2024 | −2.1% | +1.3% | −3.5% | −11.9% |
| November 8, 2023 | −5.6% | −0.7% | −8.3% | +20.6% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $6.1B
- Institutions reporting
- 314
- Shares held vs prior quarter
- ▲ 0.7%
- Positions opened / closed
- 46 / 22
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $582M | 9.6M | 9.6% | ▼ 10.8% |
| Blackrock, Inc. | $454M | 7.5M | 7.4% | ▲ 33.4% |
| Avoro Capital Advisors LLC | $349M | 5.8M | 5.7% | 0.0% |
| Polar Capital Holdings PLC | $276M | 4.6M | 4.5% | ▲ 3.8% |
| Driehaus Capital Management LLC | $267M | 4.4M | 4.4% | ▼ 1.6% |
| Jupiter Topco LLC | $253M | 4.2M | 4.1% | — |
| Price T Rowe Associates Inc | $196M | 3.2M | 3.2% | ▲ 144.3% |
| Jpmorgan Chase & Co | $157M | 2.6M | 2.6% | ▲ 36.1% |
| Capital International Investors | $143M | 2.4M | 2.3% | ▼ 11.7% |
| T. Rowe Price Investment Management, Inc. | $131M | 2.2M | 2.1% | ▲ 127.8% |
| State Street Corp | $119M | 2.0M | 2.0% | ▲ 14.5% |
| Two Sigma Investments, LP | $99.2M | 1.6M | 1.6% | ▲ 171.1% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Xenon Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $1.7M 2 trades by 2 insiders, last 12 months Insider sales History → $22M 26 trades by 6 insiders · 97% under pre-set plans
Net ▼ $20.3M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Mortimer Ian PRESIDENT & CEO | September 30, 2026 | Buy | 30,000 | $37.38 | $1.1M |
| Kelly Thomas Patrick Chief Financial Officer | September 30, 2026 | Buy | 15,000 | $37.32 | $559,740 |
| Kenney Christopher John Chief Medical Officer | August 28, 2026 | Sell pre-set plan | 700 | $60.98 | $42,686 |
| Kenney Christopher John Chief Medical Officer | August 28, 2026 | Sell pre-set plan | 6,368 | $60.17 | $383,163 |
| Gannon Steven Director | August 11, 2026 | Sell | 10,000 | $64.06 | $640,600 |
| Cannon Gillian Director | June 5, 2026 | Sell pre-set plan | 1,190 | $53.14 | $63,237 |
| Patou Gary Director | June 5, 2026 | Sell pre-set plan | 1,322 | $53.14 | $70,251 |
| Mortimer Ian PRESIDENT & CEO | March 13, 2026 | Sell pre-set plan | 7,308 | $55.23 | $403,621 |
| Difabio Andrea Chief Legal Officer | March 13, 2026 | Sell pre-set plan | 1,342 | $55.23 | $74,119 |
| Kenney Christopher John Chief Medical Officer | March 13, 2026 | Sell pre-set plan | 1,410 | $55.23 | $77,874 |
| Mortimer Ian PRESIDENT & CEO | March 10, 2026 | Sell pre-set plan | 11,269 | $60.11 | $677,380 |
| Difabio Andrea Chief Legal Officer | March 10, 2026 | Sell pre-set plan | 2,607 | $60.11 | $156,707 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced
- August 6, 2026
- May 7, 2026
- February 26, 2026
- November 3, 2025
- August 11, 2025
- May 12, 2025
Recent SEC filings
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Xenon Pharmaceuticals Inc. in brief
- What does Xenon Pharmaceuticals Inc. do?
- Xenon Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Xenon Pharmaceuticals Inc.'s stock ticker?
- Xenon Pharmaceuticals Inc. trades under the ticker XENE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Xenon Pharmaceuticals Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Blackrock, Inc. and Avoro Capital Advisors LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Xenon Pharmaceuticals Inc. stock?
- Over the last 12 months, Xenon Pharmaceuticals Inc.'s directors and officers reported 2 open-market purchases and 26 sales on Form 4. The insider trading page charts every trade.
Follow research on Xenon Pharmaceuticals Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.